[go: up one dir, main page]

HK40007107B - 溶血-gb1作为可药化靶标的用途 - Google Patents

溶血-gb1作为可药化靶标的用途 Download PDF

Info

Publication number
HK40007107B
HK40007107B HK19130577.0A HK19130577A HK40007107B HK 40007107 B HK40007107 B HK 40007107B HK 19130577 A HK19130577 A HK 19130577A HK 40007107 B HK40007107 B HK 40007107B
Authority
HK
Hong Kong
Prior art keywords
disease
lyso
animal model
glucocerebrosidase
parkinson
Prior art date
Application number
HK19130577.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK40007107A (zh
Inventor
Cozma Claudia
Bauer Peter
Original Assignee
Centogene Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centogene Gmbh filed Critical Centogene Gmbh
Publication of HK40007107A publication Critical patent/HK40007107A/zh
Publication of HK40007107B publication Critical patent/HK40007107B/zh

Links

HK19130577.0A 2016-07-01 2017-07-03 溶血-gb1作为可药化靶标的用途 HK40007107B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16001474.2 2016-07-01

Publications (2)

Publication Number Publication Date
HK40007107A HK40007107A (zh) 2020-05-29
HK40007107B true HK40007107B (zh) 2025-02-14

Family

ID=

Similar Documents

Publication Publication Date Title
Sudhakar et al. Lumenal Galectin-9-Lamp2 interaction regulates lysosome and autophagy to prevent pathogenesis in the intestine and pancreas
Mielke et al. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease
Aydin et al. Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders
JP5955219B2 (ja) 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
Kolodny Niemann-Pick disease
Cao et al. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice
ES2659753T3 (es) Método para el diagnóstico de la enfermedad de Gaucher
Kitagawa et al. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry
EP4342534A2 (en) Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury
Takahashi et al. Reduced progranulin increases tau and α-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase
Khalil et al. Association of serum ferritin with insulin resistance in offsprings of type 2 diabetics
EP3479123B1 (en) Use of lyso-gb1 as druggable target
Lozano et al. Effect of amyloid-Β (25–35) in hyperglycemic and hyperinsulinemic rats, effects on phosphorylation and O-GlcNAcylation of tau protein
EP4170032A1 (en) Method for determining disease caused by synaptic dysfunction or disease accompanied by synaptic dysfunction
HK40007107A (zh) 溶血-gb1作为可药化靶标的用途
HK40007107B (zh) 溶血-gb1作为可药化靶标的用途
Koeppen et al. The heterogeneous distribution of brain transferrin
Warnock et al. Renal manifestations of Fabry disease
US20090239807A1 (en) Methods and kits for diagnosing and/or assessing severity and treating gaucher disease
Tural et al. The probable role of insulin resistance and SIRT1 proteins in the Alzheimer's disease.
Kato et al. TrkB phosphorylation in serum extracellular vesicles correlates with cognitive function enhanced by ergothioneine in humans
AL-NAAMA et al. The Role of Islet Cell Autoantibodies, Islet Cell Antigen-2 Antibody and Antioxidant Enzymes in Diabetic Patients Type 2
RU2780331C2 (ru) Способ диагностики болезни гоше
Huang et al. Intracerebroventricular delivery of glatiramer acetate: proof-of-concept for the treatment of Alzheimer’s disease by promoting innate phagocytosis and antagonizing amyloid-β toxicity
Bahleem Risk Profile in Reference to Glycated Hemoglobin and Lipid Profile in Stroke Patient with Type-2 Diabetes Mellitus